ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310

SAN DIEGO and SHANGHAI: SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ — ABM Therapeutics (ABM), a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases, today announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the National Medical Products Administration (NMPA) to conduct Phase 1 clinical trials in patients of advanced solid tumors with BRAF mutation in China. This is the first clinical candidate and IND approval obtained by ABM Therapeutics in China.
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks